{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T11:22:23Z","timestamp":1761823343066},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2011,1,8]],"date-time":"2011-01-08T00:00:00Z","timestamp":1294444800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Neurooncol"],"published-print":{"date-parts":[[2011,9]]},"DOI":"10.1007\/s11060-010-0519-8","type":"journal-article","created":{"date-parts":[[2011,1,7]],"date-time":"2011-01-07T11:37:27Z","timestamp":1294400247000},"page":"595-598","source":"Crossref","is-referenced-by-count":13,"title":["Dural venous sinus thrombosis in anaplastic astrocytoma following concurrent temozolomide and focal brain radiotherapy plus bevacizumab"],"prefix":"10.1007","volume":"104","author":[{"given":"J. A.","family":"Vargo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B. M.","family":"Snelling","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E. R.","family":"Ghareeb","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K.","family":"John","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J. N.","family":"Frame","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J. H.","family":"Schmidt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K. B.","family":"Peters","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2011,1,8]]},"reference":[{"key":"519_CR1","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1634\/theoncologist.2009-0121","volume":"14","author":"MH Cohen","year":"2009","unstructured":"Cohen MH, Shen YL, Keegan P, Pazdur R (2009) FDA drug approval summary: bevacizumab (Avastin) as treatment of recurrent glioblastoma multiforme. The Oncologist 14:1131\u20131138","journal-title":"The Oncologist"},{"key":"519_CR2","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1002\/ajh.21277","volume":"83","author":"F Elice","year":"2008","unstructured":"Elice F, Jacoub J, Rickles FR, Falanga A, Rodeghiero F (2008) Hemostatic complications of angiogenesis inhibitors in cancer patients. Am J Hematol 83:862\u2013870","journal-title":"Am J Hematol"},{"key":"519_CR3","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1159\/000088481","volume":"69","author":"MS Gordon","year":"2005","unstructured":"Gordon MS, Cunningham D (2005) Managing patients treated with bevacizumab combination therapy. Oncology 69:25\u201333","journal-title":"Oncology"},{"key":"519_CR4","doi-asserted-by":"crossref","first-page":"S41","DOI":"10.1016\/S0049-3848(07)70129-9","volume":"120","author":"AA Khorana","year":"2007","unstructured":"Khorana AA, Rao MV (2007) Approaches to risk-stratifying cancer patients for venous thromboembolism. Thromb Res 120:S41\u2013S50","journal-title":"Thromb Res"},{"key":"519_CR5","doi-asserted-by":"crossref","first-page":"1372","DOI":"10.1016\/j.ijrobp.2007.11.068","volume":"71","author":"A Lai","year":"2008","unstructured":"Lai A, Filka E, McGibbon B, Nghiemphu PL, Graham C, Yong WH, Mischel P, Liau LM, Bergsneider M, Pope W, Selch M, Cloughesy T (2008) Phase II pilot study of bevacizumab in combination with temozolomide and regional radiation therapy for up-front treatment of patients with newly diagnosed glioblastoma multiforme: interim analysis of safety and tolerability. Int J Radiat Oncol Biol Phys 71:1372\u20131380","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"519_CR6","doi-asserted-by":"crossref","unstructured":"Vredenburgh JJ, Desjardins A, Reardon DA, Peters K, Herndon JE, Kirkpatrick J, Gururangan S, Baily L, Friedman AH, Friedman HS (2009) Safety and efficacy of the addition of bevacizumab (BV) to temozolomide (TMZ) and radiation therapy (RT) followed by BV, TMZ, and irinotecan (CPT-11) for newly diagnosed glioblastoma multiforme (GBM). J Clin Oncol 27S:2015. ASCO Annual meeting proceedings","DOI":"10.1200\/jco.2009.27.15_suppl.2015"},{"key":"519_CR7","doi-asserted-by":"crossref","first-page":"7068","DOI":"10.1158\/1078-0432.CCR-08-0260","volume":"14","author":"A Desjardins","year":"2008","unstructured":"Desjardins A, Reardon DA, Herndon JE, Marcello J, Quinn JA, Rich JN, Sathornsumetee S, Gururangan S, Sampson J, Bailey L, Bigner DD, Friedman AH, Friedman HS, Vrendenburgh JJ (2008) Bevacizumab plus irinotecan in recurrent WHO grade III malignant gliomas. Clin Cancer Res 14:7068\u20137073","journal-title":"Clin Cancer Res"},{"key":"519_CR8","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1200\/JCO.2008.16.3055","volume":"27","author":"TN Kreisl","year":"2009","unstructured":"Kreisl TN, Kim L, Moore K, Duic P, Royce C, Stroud I, Garren N, Mackey M, Butman JA, Camphausen K, Park J, Albert PS, Fine HA (2009) Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma. J Clin Oncol 27:740\u2013745","journal-title":"J Clin Oncol"},{"key":"519_CR9","doi-asserted-by":"crossref","first-page":"4722","DOI":"10.1200\/JCO.2007.12.2440","volume":"25","author":"JJ Vredenburgh","year":"2007","unstructured":"Vredenburgh JJ, Desjardins A, Herndon JE, Marcello J, Reardon DA, Quinn JA, Rich JN, Sathornsumetee S, Gururangan S, Sampson J, Wagner M, Bailey L, Darell BD, Friedman AH, Friedman HS (2007) Bevacizumab plus irinotecan in recurrent glioblastoma multiforme. J Clin Oncol 25:4722\u20134749","journal-title":"J Clin Oncol"},{"key":"519_CR10","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1158\/1078-0432.CCR-06-2309","volume":"13","author":"JJ Vrendenburgh","year":"2007","unstructured":"Vrendenburgh JJ, Desjardins A, Herndon JE, Dowell JM, Reardon DA, Quinn JA, Rich JN, Sathornsumetee S, Gururangan S, Wagner M, Bigner DD, Friedman AH, Friedman HS (2007) Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma. Clin Cancer Res 13:1253\u20131259","journal-title":"Clin Cancer Res"},{"key":"519_CR11","doi-asserted-by":"crossref","first-page":"4733","DOI":"10.1200\/JCO.2008.19.8721","volume":"27","author":"HS Friedman","year":"2009","unstructured":"Friedman HS, Prados MD, Wen PY, Mikkelsen T, Schiff D, Abrey LE, Yung WK, Paleologos N, Nicholas MK, Jensen R, Vredenburgh J, Huang J, Zheng M, Cloughesy T (2009) Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J Clin Oncol 27:4733\u20134740","journal-title":"J Clin Oncol"},{"key":"519_CR12","doi-asserted-by":"crossref","unstructured":"Vredenburgh JJ, Desjardins A, Reardon DA, Peters K, Kirkpatrick J, Herndon JE, Marcello J, Bailey L, Threatt S, Friedman HS (2010) Bevacizumab (BEV) in combination with temozolomide (TMZ) and radiation therapy (XRT) followed by BEV, TMZ, and irinotecan for newly diagnosed glioblastoma multiforme (GBM). J ClinOncol 28S:2023. ASCO Annual meeting proceedings","DOI":"10.1200\/jco.2010.28.15_suppl.2023"},{"key":"519_CR13","unstructured":"Health canada endorsed important safety Information on Avastin (bevacizumab). Available from http:\/\/www.hc-sc.gc.gc.ca\/dhp-mps\/alt_formats\/hpfb-dgpsa\/pdf\/medeff\/avastin_pc-cp-eng.pdf . Accessed 10 July 2010"},{"key":"519_CR14","unstructured":"Avastin (bevacizumab) Prescribing Information. Available from http:\/\/www.gene.com\/gene\/products\/information\/pdf\/avastin-prescribing.pdf . Accessed 10 July 2010"},{"key":"519_CR15","doi-asserted-by":"crossref","first-page":"2277","DOI":"10.1001\/jama.2008.656","volume":"300","author":"SR Nalluri","year":"2008","unstructured":"Nalluri SR, Chu D, Keresztes R, Zhu X, Wu S (2008) Risk of venous thromboembolism with the angiogenesis inhibitor bevacizumab in cancer patients: a meta-analysis. JAMA 300:2277\u20132285","journal-title":"JAMA"},{"key":"519_CR16","first-page":"4309","volume":"10","author":"E Pan","year":"2009","unstructured":"Pan E, Tsai JS, Mitchell SB (2009) Retrospective study of venous thromboembolic and intracereberal hemorrhagic events in glioblastoma patients. Anticancer Res 10:4309\u20134313","journal-title":"Anticancer Res"},{"key":"519_CR17","doi-asserted-by":"crossref","first-page":"130","DOI":"10.4103\/0973-1482.52791","volume":"5","author":"A Ozen","year":"2009","unstructured":"Ozen A, Cicin I, Sezer A, Uzunoglu S, Saynak M, Genchellac H, Karagol H (2009) Dural sinus vein thrombosis in a patient with colon cancer treated with FOLFIRI\/bevacizumab. J Can Res Ther 5:130\u2013132","journal-title":"J Can Res Ther"},{"key":"519_CR18","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1161\/01.STR.0000117571.76197.26","volume":"35","author":"JM Ferro","year":"2004","unstructured":"Ferro JM, Canh\u00e3o P, Stam J, Bousser MG, Barinagarrementeria F, Investigators ISCVT (2004) Prognosis of cerebral vein and dural sinus thrombosis: results of the international study on cerebral vein and dural sinus thrombosis. Stroke 35:664\u2013670","journal-title":"Stroke"},{"key":"519_CR19","doi-asserted-by":"crossref","first-page":"E3","DOI":"10.3171\/2009.8.FOCUS09167","volume":"27","author":"A Filippidis","year":"2009","unstructured":"Filippidis A, Kapsalaki E, Patramani G, Fountas KN (2009) Cerebral venous sinus thrombosis: review of the demographics, pathophysiology, current diagnosis, and treatment. Neurosurg Focus 27:E3","journal-title":"Neurosurg Focus"},{"key":"519_CR20","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.1212\/WNL.54.6.1222","volume":"54","author":"JJ Razier","year":"2000","unstructured":"Razier JJ, DeAngelis LM (2000) Cerebral sinus thrombosis diagnosed by MRI and MR venography in cancer patients. Neurology 54:1222\u20131226","journal-title":"Neurology"}],"container-title":["Journal of Neuro-Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11060-010-0519-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11060-010-0519-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11060-010-0519-8","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,11,17]],"date-time":"2021-11-17T02:04:58Z","timestamp":1637114698000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11060-010-0519-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,1,8]]},"references-count":20,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2011,9]]}},"alternative-id":["519"],"URL":"https:\/\/doi.org\/10.1007\/s11060-010-0519-8","relation":{},"ISSN":["0167-594X","1573-7373"],"issn-type":[{"value":"0167-594X","type":"print"},{"value":"1573-7373","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,1,8]]}}}